Organon & Company Aktie
| 15,00USD | 0,28USD | 1,87% |
WKN DE: A3CPKP / ISIN: US68622V1061
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,78 |
| The Vanguard Group, Inc. | 11,88 |
| Vanguard Group, Inc. (Subfiler) | 11,56 |
| BlackRock Fund Advisors | 8,84 |
| iShares Core S&P Small Cap ETF | 6,36 |
| Mawer Investment Management Ltd. | 4,99 |
| Massachusetts Financial Services Co. | 3,79 |
| SSgA Funds Management, Inc. | 3,69 |
| State Street Corp. | 3,49 |
| Vanguard Total Stock Market ETF | 3,15 |
| LSV Asset Management | 2,91 |
| Nordea Investment Management AB (Denmark) | 2,62 |
| BlackRock Institutional Trust Co. NA | 2,55 |
| Vanguard Small Cap Index Fund | 2,50 |
| Janus Henderson Contrarian Fund | 2,16 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 10 445 | 9 950 | 9 300 | 10 000 | 10 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,91 | 0,81 | 0,68 | 0,62 | 0,63 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 3 955 | 3 378 | 3 760 | 3 931 | 4 508 |
| Summe Anlagevermögen | 6 593 | 6 542 | 6 921 | 7 024 | 7 550 |
| Summe Aktiva | 10 548 | 9 920 | 10 681 | 10 955 | 12 058 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 186 | 1 241 | 9 364 | 9 112 | 8 931 |
| Summe Fremdkapital | 3 513 | 4 434 | 12 189 | 11 847 | 12 128 |
| Summe Eigenkapital | 7 035 | 5 486 | -1 508 | -892 | -70 |
| Summe Passiva | 10 548 | 9 920 | 10 681 | 10 955 | 12 058 |
Adresse
| 30 Hudson Street, 07302 Jersey City | |
| Telefon | +1 (551) 430-6900 |
| Internet | http://www.organon.com |
Management
|
Aaron Falcione
Chief Human Resources Officer |
|
Carrie Smith Cox
Chairman |
|
Charlotte Owens
Head-Medical Affairs & Outcomes Research |
|
Cynthia M. Patton
Independent Director |
|
Daniel Karp
Chief Business Development Officer |
|
Deborah R. Leone
Independent Director |
|
Grace Puma Whiteford
Independent Director |
|
Helene D. Gayle
Independent Director |
|
Jennifer Halchak
Head-Investor Relations |
|
Joseph T. Morrissey
Executive VP, Head-Manufacturing & Supply |
|
Juan Camilo Arjona Ferreira
Chief Medical Officer & Head- R&D |
|
Kate C. Liebelt
Chief of Staff & Executive Director |
|
Kathryn DiMarco
Senior Vice President-Finance & Controller |
|
Kevin Ali
Chief Executive Officer & Director |
|
Kirke Weaver
Secretary, Executive VP & General Counsel |
|
Ma. Fatima D. de Vera Francisco
Independent Director |
|
Marcel van Duin
Chief Scientific Officer |
|
Martha E. McGarry
Independent Director |
|
Matthew M. Walsh
Chief Financial Officer & Executive Vice President |
|
Michael Pergine
Chief Government Affairs & Policy Officer |
|
Philip O. Ozuah
Independent Director |
|
R. Alan B. Ezekowitz
Independent Director |
|
Rachel A. Stahler
Chief Information Officer & Executive VP |
|
Rebecca Lowell Edwards
Chief Communications Officer |
|
Robert A. Essner
Independent Director |
|
Rochelle B. Lazarus
Independent Director |
|
Shalini Sharp
Independent Director |
|
Susan O'Neal
Chief Ethics & Compliance Officer |
|
Susanne Gabriele Fiedler
Chief Commercial Officer & Executive VP |
|
Vittorio Nisita
Executive VP & Head-Global Business Services |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
